European journal of pharmacology · 2025
Repositioning drugs for autism spectrum disorder: An integrated network analysis of blood and brain tissue key driver genes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Chuyun, He Qian, Bennett Adam N, Pu Yuping, Wang Tailin, Chan Kei Hang Katie
Аннотация
BACKGROUND: Autism spectrum disorder (ASD) is a complex neurological condition marked by social, communication, and behavioral challenges. Current treatments are limited, with few approved drugs. This study used network analysis of key driver genes from blood and brain tissues to identify potential therapeutic drugs for ASD.
METHOD: We examined Gene Expression Omnibus (GEO) data from postmortem brain (GSE28521) and blood leukocyte (GSE42133) samples to find differentially expressed genes. Key driver genes were identified using weighted key driver analysis, supported by literature, knockout mouse model databases, and enrichment analysis. Drug repositioning was performed with PharmOmics and Connectivity Map (CMap) platforms.
RESULTS: In blood samples, 204 key driver genes were discovered, associated with cell cycle regulation and stress response. In brain samples, 290 key driver genes focused on ribosomal activity and protein production. An integrated protein-protein interaction (PPI) network identified 16 shared key driver genes, demonstrating common disease signatures including RNA metabolism, protein regulation, SLIT and ROBO signaling, and antiviral pathways. Drug repositioning revealed 23 potential drugs for ASD, with sulpiride and everolimus demonstrating promise, and 19 drugs exhibiting neurological significance, including six with substantial blood-brain barrier permeability.
CONCLUSIONS: Our study reveals both tissue-specific and shared molecular signatures of ASD in blood and brain tissues through PPI network analysis. We identified 16 key driver genes and 23 potential therapeutic drugs. Additionally, we discovered twelve novel key driver genes associated with ASD, emphasizing their roles in neurological and immune functions. These findings enhance our understanding of the molecular basis of ASD and suggest new therapeutic possibilities.
METHOD: We examined Gene Expression Omnibus (GEO) data from postmortem brain (GSE28521) and blood leukocyte (GSE42133) samples to find differentially expressed genes. Key driver genes were identified using weighted key driver analysis, supported by literature, knockout mouse model databases, and enrichment analysis. Drug repositioning was performed with PharmOmics and Connectivity Map (CMap) platforms.
RESULTS: In blood samples, 204 key driver genes were discovered, associated with cell cycle regulation and stress response. In brain samples, 290 key driver genes focused on ribosomal activity and protein production. An integrated protein-protein interaction (PPI) network identified 16 shared key driver genes, demonstrating common disease signatures including RNA metabolism, protein regulation, SLIT and ROBO signaling, and antiviral pathways. Drug repositioning revealed 23 potential drugs for ASD, with sulpiride and everolimus demonstrating promise, and 19 drugs exhibiting neurological significance, including six with substantial blood-brain barrier permeability.
CONCLUSIONS: Our study reveals both tissue-specific and shared molecular signatures of ASD in blood and brain tissues through PPI network analysis. We identified 16 key driver genes and 23 potential therapeutic drugs. Additionally, we discovered twelve novel key driver genes associated with ASD, emphasizing their roles in neurological and immune functions. These findings enhance our understanding of the molecular basis of ASD and suggest new therapeutic possibilities.